Highbridge Capital Management’s Albany Molecular Research Inc AMRI Stock Holding History

Highbridge Capital Management’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-108,700	Closed	-$2.36M	–	1959
2017 Q2	$2.36M	Buy	+108,700	New	+$1.97M	0.04%	407
2015 Q2	–	Sell	-26,000	Closed	-$458K	–	1837
2015 Q1	$458K	Buy	+26,000	New	+$443K	0.01%	995

Other funds holding AMRI

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Highbridge Capital Management's AMRI Position: Q3 2017 in Review

Highbridge Capital Management sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 150,000 shares — an estimated $3.25M sold.

Highbridge Capital Management first reported a position in AMRI in Q2 2013 and held it in 5 quarters. The position peaked at $3.25M in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

Highbridge Capital Management reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
Highbridge Capital Management sold 150,000 Albany Molecular Research Inc shares in Q3 2017, an estimated $3.25M.
Highbridge Capital Management first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 5 quarters.
Highbridge Capital Management's Albany Molecular Research Inc position peaked at $3.25M in Q2 2017.
2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on Highbridge Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.